HC Wainwright restated their buy rating on shares of Trevena, Inc. (NASDAQ:TRVN) in a research note published on Wednesday. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also commented on TRVN. Zacks Investment Research lowered shares of Trevena from a buy rating to a hold rating in a report on Friday, August 25th. Cowen and Company reiterated a buy rating and set a $10.00 target price on shares of Trevena in a report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 target price on shares of Trevena and gave the company a buy rating in a report on Thursday, October 12th. Needham & Company LLC lowered their target price on shares of Trevena from $9.00 to $7.00 and set a buy rating for the company in a report on Wednesday. Finally, Barclays PLC lowered shares of Trevena from an overweight rating to an equal weight rating and lowered their target price for the company from $15.00 to $2.50 in a report on Monday, October 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. Trevena currently has a consensus rating of Buy and a consensus price target of $8.75.

Shares of Trevena (TRVN) traded up $0.08 on Wednesday, reaching $1.78. 1,279,300 shares of the company’s stock traded hands, compared to its average volume of 771,489. The company has a quick ratio of 7.15, a current ratio of 4.92 and a debt-to-equity ratio of 0.38. Trevena has a twelve month low of $1.35 and a twelve month high of $8.00.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.06. During the same quarter in the previous year, the business earned ($0.57) earnings per share. sell-side analysts predict that Trevena will post -1.28 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/trevena-inc-trvn-earns-buy-rating-from-hc-wainwright/1696277.html.

A number of large investors have recently bought and sold shares of TRVN. American International Group Inc. grew its position in Trevena by 7.1% in the 1st quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 1,816 shares during the period. Nationwide Fund Advisors grew its position in Trevena by 92.1% in the 2nd quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 23,557 shares during the period. Bourgeon Capital Management LLC grew its position in Trevena by 56.8% in the 2nd quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 19,200 shares during the period. Alliancebernstein L.P. grew its position in Trevena by 51.9% in the 2nd quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 18,900 shares during the period. Finally, SG Americas Securities LLC grew its position in Trevena by 81.0% in the 1st quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 16,079 shares during the period. 60.27% of the stock is owned by institutional investors and hedge funds.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.